Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension

Sacubitril/valsartan (LCZ696), a novel angiotensin receptor-neprilysin inhibitor, was recently approved for the treatment of heart failure with reduced ejection fraction. Neprilysin degrades several peptides that modulate lipid metabolism, including natriuretic peptides. In this study, we investigat...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Hypertension
Prif Awduron: Engeli, Stefan, Stinkens, Rudi, Heise, Tim, May, Marcus, Goossens, Gijs H., Blaak, Ellen E., Havekes, Bas, Jax, Thomas, Albrecht, Diego, Pal, Parasar, Tegtbur, Uwe, Haufe, Sven, Langenickel, Thomas H., Jordan, Jens
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Lippincott, Williams & Wilkins 2018
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5753808/
https://ncbi.nlm.nih.gov/pubmed/29180454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/HYPERTENSIONAHA.117.10224
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg